Substrate-Based Ablation for Post-Infarction Ventricular Tachycardia
Post-infarction ventricular tachycardia (VT) is usually the clinical expression of a mature ventricular scar. Following myocardial infarction, surviving myocardial bundles can become electrically isolated within fibrotic tissue. These channels support slow conduction and unidirectional block, creating the conditions for a re-entrant circuit. The resulting arrhythmia may cause palpitations, syncope, recurrent implantable cardioverter-defibrillator (ICD) therapies, or sudden cardiac death.
Catheter ablation has therefore moved beyond treating a single inducible tachycardia. In many patients, the procedural goal is to identify and modify the arrhythmogenic substrate that permits several related VT morphologies. This strategy is particularly valuable when VT is poorly tolerated, when antiarrhythmic medication is ineffective or poorly tolerated, or when repeated ICD shocks impair quality of life.
Substrate-based approaches combine electroanatomic mapping, intracardiac signals, imaging, and programmed stimulation. Their application requires careful attention to ventricular function, coronary anatomy, scar location, procedural risk, and the patient’s broader heart-failure and device-management plan.
Why infarct scar sustains ventricular tachycardia
An infarct scar is electrically heterogeneous rather than uniformly inert. Dense fibrosis may be surrounded by border-zone tissue containing strands of viable myocardium, causing marked conduction slowing. These surviving bundles can form protected isthmuses between areas of scar or between scar and anatomical boundaries. During a premature beat, conduction block and delayed activation can establish a stable re-entry pathway.
The substrate may be located in the endocardium, within the myocardial wall, or predominantly on the epicardial surface. Inferior and posterior infarctions can be associated with intramural or epicardial circuits, while anterior infarctions often produce extensive septal and apical substrate. These patterns are useful guides, but individual anatomy varies substantially.
Clinical VT may represent only one exit from a larger circuit. A procedure directed solely at the presenting tachycardia can leave adjacent channels intact, allowing another morphology to emerge later. Substrate modification seeks to address this broader arrhythmogenic network while avoiding unnecessary injury to viable myocardium.
Mapping the arrhythmogenic substrate
High-density voltage mapping during sinus rhythm is central to contemporary post-infarction VT ablation. Areas of very low bipolar voltage generally indicate dense scar, whereas intermediate-voltage regions may contain the surviving fibers that sustain re-entry. Unipolar voltage can provide additional information about deeper or intramural disease, particularly when the endocardial map appears less extensive than expected.
Abnormal electrograms help refine the target. Late potentials, fractionated signals, split potentials, and local abnormal ventricular activities (LAVAs) may identify delayed activation within or around the scar. These signals should be interpreted in relation to timing, reproducibility, catheter stability, and anatomical position. A small electrogram alone does not prove that a site is part of the critical circuit.
Pace mapping, entrainment, and activation mapping remain important when VT is hemodynamically tolerated. Entrainment can distinguish a critical isthmus from a bystander region, while pace mapping may identify a likely exit when sustained activation mapping is impractical. When VT causes hypotension or cannot be maintained safely, sinus-rhythm substrate mapping and targeted ventricular stimulation become the foundation of the procedure.
From scar characterization to ablation strategy
A practical workflow begins with a review of the infarct territory, left ventricular ejection fraction, prior revascularization, ICD records, and available cardiac magnetic resonance imaging. Late gadolinium enhancement can show scar transmurality and distribution, helping the operator anticipate whether an endocardial approach is likely to be sufficient. Imaging does not replace invasive mapping, but it can improve procedural planning and identify challenging septal, basal, or epicardial regions.
The ablation plan commonly includes elimination of abnormal potentials, interruption of conduction channels, and creation of lesions across selected areas of scar. Operators may use linear lesions to connect scar to an anatomical boundary or to transect a suspected isthmus. The appropriate endpoint is individualized; complete elimination of every abnormal signal may be neither achievable nor necessary, particularly when the substrate is extensive or close to critical structures.
| Procedural element | Clinical purpose | Important limitation |
|---|---|---|
| Bipolar voltage mapping | Defines endocardial scar and border zones | May underestimate intramural or epicardial scar |
| Unipolar voltage mapping | Suggests deeper myocardial involvement | Less specific for the exact re-entry channel |
| Late-potential and LAVA mapping | Identifies delayed, potentially arrhythmogenic tissue | Signals may be difficult to distinguish from far-field activity |
| Pace mapping | Localizes a likely VT exit | Accuracy falls with multiple exits or poor capture |
| Entrainment mapping | Tests whether a site lies within or near the circuit | Requires a tolerated, stable VT |
| Cardiac MRI integration | Relates scar anatomy to procedural targets | Image quality and device compatibility can limit use |
| Programmed stimulation | Assesses inducibility and procedural endpoint | Noninducibility does not guarantee long-term freedom from VT |
Substrate modification can be performed with a limited approach directed at the clinical VT or with a more extensive strategy covering the infarct border zone and all identifiable channels. The choice depends on the number of VT morphologies, prior ablation, scar complexity, ventricular function, and operator experience. Extensive ablation may improve arrhythmia control in selected patients, but it can increase procedure time and myocardial injury.
Endocardial, epicardial, and intramural considerations
Most post-infarction VT procedures begin from the left ventricular endocardium, often through a transseptal or retrograde aortic approach. Endocardial mapping allows assessment of the scar, mitral and aortic continuity, papillary muscles, and septal regions. Anticoagulation, vascular access management, and attention to coronary ostia are essential components of procedural safety.
An epicardial approach may be considered when the suspected substrate is epicardial, when endocardial ablation fails, or when surface ECG features and imaging suggest an outward-facing circuit. The operator must account for pericardial bleeding, phrenic nerve injury, coronary artery damage, and adhesions from previous surgery or inflammation. Coronary angiography is often required before delivering energy near epicardial vessels.
Intramural circuits create a particularly difficult problem because conventional endocardial lesions may not reach the target. Strategies can include bipolar ablation between opposing endocardial surfaces, sequential unipolar applications, needle or needle-like technologies where available, and carefully selected epicardial intervention. These approaches require specialized expertise and should be reserved for circumstances in which the anticipated benefit justifies the added risk.
Integrating ablation with ICD and medical therapy
An ICD remains central to protection against sudden death in many patients with ischemic cardiomyopathy, even after apparently successful ablation. Ablation reduces recurrent VT and shocks; it does not remove the underlying risk associated with scar, reduced ventricular function, or future disease progression. Device interrogation before and after the procedure is necessary to distinguish true VT from supraventricular tachycardia, oversensing, lead noise, or inappropriate therapy.
Programming can substantially influence the patient’s experience between procedures. Longer detection intervals, appropriate antitachycardia pacing, and discriminators may reduce unnecessary shocks in selected patients. A clinically useful discussion of advanced ICD discrimination illustrates how device programming complements ablation rather than competing with it.
Antiarrhythmic drugs may be continued, reduced, or stopped according to recurrence risk, renal and hepatic function, QT effects, pulmonary toxicity, and patient preference. Amiodarone, sotalol, mexiletine, and beta-blockers each have different roles and limitations. Management should also address ischemia, heart failure, electrolyte disturbances, sleep-disordered breathing, and adherence to guideline-directed medical therapy.
Selecting patients and measuring outcomes
Early referral is appropriate for patients with recurrent sustained monomorphic VT, repeated appropriate ICD therapies, or a first sustained VT in circumstances where ablation is favored by the clinical team. Recurrent electrical storm requires urgent stabilization, including sedation when appropriate, correction of reversible triggers, sympathetic suppression, and consideration of mechanical circulatory support in selected cases. Ablation timing should reflect hemodynamic stability and the severity of the arrhythmia burden.
Risk assessment includes left ventricular function, renal disease, frailty, anticoagulation needs, vascular access, and the likelihood of requiring epicardial or advanced intramural techniques. In patients with severely impaired ventricular function, a procedure may still be reasonable, but the team should plan for anesthesia-related deterioration and possible hemodynamic support.
Outcome assessment should extend beyond acute VT noninducibility. Relevant measures include freedom from recurrent sustained VT, appropriate ICD therapy, electrical storm, hospitalization, mortality, heart-failure status, and health-related quality of life. Follow-up should include device review, medication reassessment, imaging when indicated, and reinforcement of warning signs that require urgent evaluation. Evidence continues to evolve across procedural techniques and patient subgroups, making curated resources such as the journal’s special issues useful for clinicians tracking emerging data.
Practical recommendations for clinical teams
Substrate-based ablation is most effective when mapping findings are integrated with the patient’s infarct history and the mechanism of the documented arrhythmia. A structured approach can improve consistency across referral, procedure, and follow-up:
- Review stored ICD electrograms and 12-lead VT recordings before mapping whenever they are available.
- Use cardiac imaging and infarct anatomy to anticipate endocardial, epicardial, septal, or intramural substrate.
- Combine voltage maps with abnormal electrogram analysis, pace mapping, entrainment, and programmed stimulation rather than relying on one marker.
- Define a realistic procedural endpoint that balances arrhythmia control with preservation of viable myocardium and procedural safety.
- Coordinate ablation with ICD programming, antiarrhythmic therapy, heart-failure care, and long-term device surveillance.
The field is moving toward more precise substrate characterization, improved high-density mapping, and individualized lesion delivery. Future strategies may combine imaging-derived scar architecture, automated electrogram analysis, and real-time assessment of lesion formation to identify critical channels with less unnecessary ablation.
For clinicians, researchers, and trainees, careful documentation of mapping criteria, ablation endpoints, complications, and longitudinal ICD outcomes will help clarify which substrate strategies provide durable benefit. Applying these principles in a multidisciplinary electrophysiology program can reduce recurrent ventricular arrhythmia while keeping patient safety and functional recovery at the center of care.